Author:
Szałapata Katarzyna,Pięt Mateusz,Kasela Martyna,Grąz Marcin,Kapral-Piotrowska Justyna,Mordzińska-Rak Aleksandra,Samorek Elżbieta,Pieniądz Paulina,Polak Jolanta,Osińska-Jaroszuk Monika,Paduch Roman,Pawlikowska-Pawlęga Bożena,Malm Anna,Jarosz-Wilkołazka Anna
Abstract
AbstractThe modification of the surgical polypropylene mesh and the polytetrafluoroethylene vascular prosthesis with cecropin A (small peptide) and puromycin (aminonucleoside) yielded very stable preparations of modified biomaterials. The main emphasis was placed on analyses of their antimicrobial activity and potential immunomodulatory and non-cytotoxic properties towards the CCD841 CoTr model cell line. Cecropin A did not significantly affect the viability or proliferation of the CCD 841 CoTr cells, regardless of its soluble or immobilized form. In contrast, puromycin did not induce a significant decrease in the cell viability or proliferation in the immobilized form but significantly decreased cell viability and proliferation when administered in the soluble form. The covalent immobilization of these two molecules on the surface of biomaterials resulted in stable preparations that were able to inhibit the multiplication of Staphylococcus aureus and S. epidermidis strains. It was also found that the preparations induced the production of cytokines involved in antibacterial protection mechanisms and stimulated the immune response. The key regulator of this activity may be related to TLR4, a receptor recognizing bacterial LPS. In the present study, these factors were produced not only in the conditions of LPS stimulation but also in the absence of LPS, which indicates that cecropin A- and puromycin-modified biomaterials may upregulate pathways leading to humoral antibacterial immune response.
Funder
National Science Centre in Poland
Publisher
Springer Science and Business Media LLC